Alzheimer Disease & Dementia

Shared pathophysiology between Alzheimer disease and autism may expand diagnosis and treatment opportunities.

AD/PD 2026 highlights oral blarcamesine preserving brain volume and IV lecanemab sustaining use while clearing amyloid-beta.

Early-life immigration may heighten dementia risk yet build resilience.

FDA reviews INmune Bio’s biomarker-enriched Phase 2b/3 plan for XPro1595.

Data and Safety Monitoring Board finds no safety issues for buntanetap at 6 months, keeping Annovis’ phase 3 early Alzheimer disease trial on track as enrollment progresses.

Cognition extends zervimesine expanded access for Lewy body dementia, adding months of dosing and easier local monitoring.

Research reveals links between gut microbiome composition and cognitive decline in Alzheimer disease and mild cognitive impairment.

New research reveals midlife ADHD patients exhibit early Alzheimer disease biomarkers.

Cassava Sciences shares insights from phase 3 trials of simufilam for Alzheimer disease, revealing potential treatment differences despite unmet primary endpoints.

Cognition Therapeutics shares zervimesine's promising phase 2 results, showing safety and improved symptoms in dementia with Lewy bodies.

MapLight Therapeutics advances treatment for Alzheimer disease psychosis with FDA Fast Track designation for ML-007C-MA, targeting hallucinations and delusions.

Explore innovative treatments for schizophrenia, depression, and dementia, focusing on new medications and holistic care approaches for better patient outcomes.

Review the news from this year's Clinical Trials in Alzheimer's Disease conference.

Roche reveals promising results for trontinemab, an Alzheimer antibody, showing significant amyloid plaque reduction in patients during ongoing trials.

Recent trials reveal oral semaglutide fails to improve cognition or function in early Alzheimer disease, raising questions about its efficacy.

Merck presents promising Phase 1 trial results for MK-2214, a novel Alzheimer treatment, showcasing its potential to slow disease progression.

New neuroimaging data reveals XPro1595's potential to combat neuroinflammation in early Alzheimer’s disease, offering hope for slowing progression.

Bristol Myers Squibb expands patient enrollment in the ADEPT-2 study, exploring Cobenfy's potential for treating Alzheimer disease-related psychosis.

Explore the latest insights on lecanemab and low-dose lithium for Alzheimer disease prevention and treatment, weighing benefits and risks effectively.

Let's investigate the complexities of diagnosing and treating ADHD in older adults, highlighting its prevalence, comorbidities, and treatment challenges.

Recent studies suggest lithium may effectively prevent cognitive decline and Alzheimer disease, challenging the dominance of lecanemab in early dementia treatment.

A recent study links lower income to higher dementia risk factors, highlighting the need for targeted interventions in vulnerable populations.

Axsome Therapeutics advances AXS-05 for Alzheimer disease agitation, showing significant improvement in clinical trials and addressing critical patient needs.

Discover how advanced diagnostic tools enhance the accuracy of dementia assessments, leading to better treatment strategies and patient outcomes.